Vol. 216 No. 2, February 1, 2017. 10.1083/jcb.201607008.
After publication, the authors realized that an antibody and siRNAs used in the paper were incorrect. Specifically, the antibody reported as Cdh1 in Fig. 5 E was instead an antibody against CDH1 (Cadherin). In addition, the three siRNAs in Fig. 5 E reported as siCdh1#1, siCdh1#2, and siCdh1#3 were also inadvertently synthesized against CDH1 (Cadherin). Upon discovering the error, the authors generated three correct siRNAs against Cdh1, obtained an antibody against Cdh1, and repeated the experiment in Fig. 5 E. The incorrect resources were not used in any other part of the paper and the conclusions are not affected by this correction.
The authors also identified errors in the reported sequences of shPGAM1 #2, shPGAM1 #3, and siNC. The data resources generated were accurate. The error was only in the reported sequence in the manuscript.
Fig. 5 has been corrected and the following text corrections, in bold, have been made in the HTML and PDF versions of the article. The errors remain only in the print version.
The following antibodies were used in this study: anti-PGAM1 (NBP1-49532; Novus Biologicals), anti-CtIP (sc-271339; Santa Cruz Biotechnology, Inc.), anti-Mre11 (ab214; Abcam), anti–H2AX-pS139 (9718; Cell Signaling Technology), anti–β-actin (60008-1-Ig; Proteintech), anti–Lamin B1 (12987-1-AP; Proteintech), anti-GAPDH (60004-1-Ig; Proteintech), anti-RPA32 (ab2175; Abcam), anti–RPA32-pS4S8 (NBP1-23017; Novus Biologicals), anti-BrdU (5292; Cell Signaling Technology), anti-Cdh1 (ab3242; Abcam), anti-p21 (2947; Cell Signaling Technology), anti-RAD51 (sc-8349; Santa Cruz Biotechnology, Inc.), anti-PGD (sc-398977; Santa Cruz Biotechnology, Inc.), anti-PHGDH (ab57030; Abcam), anti-IgG (2729; Cell Signaling Technology), anti-Histone H3 (4620; Cell Signaling Technology), anti-p53 (9282; Cell Signaling Technology), anti-p73 (ab202474; Abcam), and anti–Cleaved Caspase-3 (9661; Cell Signaling Technology).
Plasmid, shRNA, and siRNA transfection
PGAM1 stably depleted cells were generated using pLKO.1 lentiviral system (Addgene). The target sequences of shRNAs were as follows: Scramble (Scr), 5′-CAAATCACAGAATCGTCGTAT-3′; shPGAM1#1, 5′-CCATCCTTTCTACAGCAACAT-3′; shPGAM1#2, 5′-CCTGTGAGAGTCTGAAGGATA-3′; and shPGAM1#3, 5′-CGCCTCAATGAGCGGCACTAT-3′.
Coding sequences of FLAG-PGAM1 and indicated mutants were cloned to pCDNA3.1 vector. Nonsense point mutations to the underlined nucleotides 5′-CCACCCATTTTACAGCAACAT-3′ in the corresponding coding sequence of PGAM1 in the pCDNA3.1 plasmid confer resistance to shRNA#1 silencing. WT or mutant PGAM1 reconstituted cells were stable lines generated by Lipofectamine 2000 (Invitrogen) transfection followed by G418 selection. The lines used in this study were selected monoclones with expression levels comparable to those of endogenous PGAM1.
For siRNA transfection, cells were plated at 30–60% confluence in OPTI-MEM serum-free medium and transfected with a specific siRNA duplex using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s instructions. siRNAs were ordered as reverse-phase HPLC–purified duplexes from Sigma-Aldrich and Shanghai GenePharma Co., Ltd. The sequences were as follows: negative control siRNA (siNC), 5′-UUCUCCGAACGUGUCACGUTT-3′; siPGAM1#1, 5′-CGACUGGUAUUCCCAUUGUTT-3′; siPGAM1#2, 5′-GUCCUGUCCAAGUGUAUCUTT-3′; si6PGD#1, 5′-GGCCAGAACUUAAUUCUGATT-3′; si6PGD#2, 5′-CUGGUGACAUCAUCAUUGATT-3′; si6PGD#3, 5′-GCUGCAUCAUUAGAAGUGUTT-3′; siPHGDH#1, 5′-CUUAGCAAAGAGGAGCUGAUA-3′; siPHGDH#2, 5′-CAGACUUCACUGGUGUCAGAU-3′; sip21#1, 5′-GAUGGAACUUCGACUUUGUTT-3′; sip21#2, 5′-CCUCUGGCAUUAGAAUUAUTT-3′; sip21#3, 5′-CAGGCGGUUAUGAAAUUCATT-3′; siCdh1#1, 5′-GGAUUAACGAGAAUGAGAATT-3′; siCdh1#2, 5′-AAUGAGAAGUCUCCCAGUCAGTT-3′; siCdh1#3, 5′-GCAACGAUGUGUCUCCCUATT-3′; sip73#1, 5′-CCAUGCCUGUUUACAAGAATT-3′; sip73#2, 5′-CCAUCCUGUACAACUUCAUTT-3′; sip73#3, 5′-GUGGAAGGCAAUAAUCUCUTT-3′; sip53#1, 5′-GUACCACCAUCCACUACAATT-3′; and sip53#2, 5′-GUAAUCUACUGGGACGGAATT-3′.